Teva Pharma (TEVA): Downside From $16 Likely, Cutting PT - Cowen
Tweet Send to a Friend
Cowen analyst, Ken Cacciatore, reiterated his Market Perform rating on shares of Teva Pharma (NYSE: TEVA) and cut his price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


